公开(公告)号：WO2021059017A1

公开(公告)日：2021-04-01

申请号：PCT/IB2020/000772

申请日：2020-09-25

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： OGURO, Yuya ,  KAMATA, Makoto ,  IKEDA, Shuhei ,  WAKABAYSAHI, Takeshi ,  TOKUNAGA, Norihito ,  KAMEI, Taku ,  ITO, Mitsuhiro ,  MATSUMOTO, Shigemitsu ,  KAMITANI, Hirotaka ,  HIRAYAMA, Takaharu ,  TANAKA, Toshio ,  BANNO, Hiroshi ,  TAKAKURA, Nobuyuki ,  YONEMORI, Jinichi ,  FUJIMOTO, Takuya

IPC: A61P43/00 ,  C07D213/61 ,  C07D213/65 ,  C07D213/68 ,  C07D221/04 ,  C07D239/34 ,  C07D333/38 ,  C07D401/12 ,  A61K31/495 ,  A61K31/444 ,  A61P25/00 ,  A61P29/00

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

公开(公告)号：WO2019189945A1

公开(公告)日：2019-10-03

申请号：PCT/JP2019/014901

申请日：2019-03-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： OGURO, Yuya ,  MATSUMOTO, Shigemitsu ,  WAKABAYASHI, Takeshi ,  TOKUNAGA, Norihito ,  KAMEI, Taku ,  ITO, Mitsuhiro ,  MIKAMI, Satoshi ,  SETO, Masaki ,  MORIMOTO, Shinji ,  NAKAMURA, Shinji ,  TAKASHIMA, Sachie ,  MURAKAMI, Masataka ,  DAINI, Masaki ,  KAMATA, Makoto ,  NAKAMURA, Minoru ,  WADA, Yasufumi ,  KAKEI, Hiroyuki ,  TAKAMI, Kazuaki ,  TAWARAISHI, Taisuke ,  AIDA, Jumpei ,  HIWANAGA, Kouichi ,  YAMAMOTO, Satoshi

IPC: C07D471/04 ,  C07D487/04 ,  A61P25/00 ,  A61K31/437 ,  A61K31/4162

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：WO2012137982A3

公开(公告)日：2012-10-11

申请号：PCT/JP2012/059949

申请日：2012-04-05

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  FUKUMOTO, Shoji ,  UJIKAWA, Osamu ,  MORIMOTO, Shinji ,  ASANO, Yasutomi ,  MIKAMI, Satoshi ,  TOKUNAGA, Norihito ,  KORI, Masakuni ,  IMAEDA, Toshihiro ,  FUKUDA, Koichiro ,  NAKAMURA, Shinji ,  IWANAGA, Kouichi

Inventor： FUKUMOTO, Shoji ,  UJIKAWA, Osamu ,  MORIMOTO, Shinji ,  ASANO, Yasutomi ,  MIKAMI, Satoshi ,  TOKUNAGA, Norihito ,  KORI, Masakuni ,  IMAEDA, Toshihiro ,  FUKUDA, Koichiro ,  NAKAMURA, Shinji ,  IWANAGA, Kouichi

IPC: C07C311/07 ,  C07C311/09 ,  C07C311/14 ,  C07C317/28 ,  C07C323/26 ,  C07D211/98 ,  C07D309/14 ,  C07D335/02 ,  A61P25/28 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61K31/18

Abstract: Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：WO2020158958A1

公开(公告)日：2020-08-06

申请号：PCT/JP2020/004444

申请日：2020-01-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： HATTORI, Yasushi ,  MIYANOHANA, Yuhei ,  KAJITA, Yuichi ,  KOIKE, Tatsuki ,  HOASHI, Yasutaka ,  TOKUNAGA, Norihito ,  PAWLICZEK, Alexander Martin ,  ODA, Tsuneo ,  MIYAZAKI, Tohru ,  ITO, Yoshiteru ,  TAKEUCHI, Kohei ,  IMAMURA, Keisuke ,  SUGIMOTO, Takahiro

IPC: A61P3/00 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  C07D207/14 ,  C07D401/10 ,  C07D403/10 ,  C07D403/14 ,  C07D407/06 ,  C07D413/10 ,  C07D417/10

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：WO2012137982A9

公开(公告)日：2012-10-11

申请号：PCT/JP2012/059949

申请日：2012-04-05

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  FUKUMOTO, Shoji ,  UJIKAWA, Osamu ,  MORIMOTO, Shinji ,  ASANO, Yasutomi ,  MIKAMI, Satoshi ,  TOKUNAGA, Norihito ,  KORI, Masakuni ,  IMAEDA, Toshihiro ,  FUKUDA, Koichiro ,  NAKAMURA, Shinji ,  IWANAGA, Kouichi

Inventor： FUKUMOTO, Shoji ,  UJIKAWA, Osamu ,  MORIMOTO, Shinji ,  ASANO, Yasutomi ,  MIKAMI, Satoshi ,  TOKUNAGA, Norihito ,  KORI, Masakuni ,  IMAEDA, Toshihiro ,  FUKUDA, Koichiro ,  NAKAMURA, Shinji ,  IWANAGA, Kouichi

IPC: C07C311/07

Abstract: Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：WO2012137982A2

公开(公告)日：2012-10-11

申请号：PCT/JP2012/059949

申请日：2012-04-05

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  FUKUMOTO, Shoji ,  UJIKAWA, Osamu ,  MORIMOTO, Shinji ,  ASANO, Yasutomi ,  MIKAMI, Satoshi ,  TOKUNAGA, Norihito ,  KORI, Masakuni ,  IMAEDA, Toshihiro ,  FUKUDA, Koichiro ,  NAKAMURA, Shinji ,  IWANAGA, Kouichi

Inventor： FUKUMOTO, Shoji ,  UJIKAWA, Osamu ,  MORIMOTO, Shinji ,  ASANO, Yasutomi ,  MIKAMI, Satoshi ,  TOKUNAGA, Norihito ,  KORI, Masakuni ,  IMAEDA, Toshihiro ,  FUKUDA, Koichiro ,  NAKAMURA, Shinji ,  IWANAGA, Kouichi

IPC: C07C311/07

CPC classification number: C07C311/07 ,  C07C311/09 ,  C07C311/14 ,  C07C317/28 ,  C07C323/26 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2603/74 ,  C07D207/27 ,  C07D207/273 ,  C07D209/04 ,  C07D211/56 ,  C07D211/58 ,  C07D211/76 ,  C07D213/61 ,  C07D213/64 ,  C07D213/85 ,  C07D231/12 ,  C07D231/14 ,  C07D233/56 ,  C07D233/68 ,  C07D237/04 ,  C07D239/28 ,  C07D261/08 ,  C07D263/32 ,  C07D277/24 ,  C07D277/32 ,  C07D277/62 ,  C07D295/092 ,  C07D295/192 ,  C07D305/06 ,  C07D307/22 ,  C07D309/06 ,  C07D309/14 ,  C07D333/16 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D493/08

Abstract: Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract translation: 提供具有AMPA受体功能增强作用的化合物，可用作抑郁症，阿尔茨海默氏病，精神分裂症，注意力缺陷多动障碍（ADHD）等的预防或治疗药物。 由式（I）表示的化合物或其盐，其中每个符号如本说明书中所定义。

公开(公告)号：EP4508027A1

公开(公告)日：2025-02-19

申请号：EP22724479.5

申请日：2022-04-12

Applicant: Takeda Pharmaceutical Company Limited

Inventor： IKEDA, Shuhei ,  PAWLICZEK, Martin Alexander ,  KIMURA, Eiji ,  HATTORI, Yasushi ,  PIRA, Marilena ,  MIGUELEZ-RAMOS, Javier ,  TOKUNAGA, Norihito ,  MIYANOHANA, Yuhei ,  HOASHI, Yasutaka ,  KAJITA, Yuichi ,  ITO, Yoshiteru ,  KOIKE, Tatsuki

IPC: C07D205/04 ,  C07D205/12 ,  C07D207/09 ,  C07D207/14 ,  C07D209/52 ,  C07D211/28 ,  C07D211/56 ,  C07D211/58 ,  C07D221/22 ,  C07D223/12 ,  C07D265/30 ,  C07D267/10 ,  C07D401/08 ,  C07D401/10 ,  C07D403/12 ,  C07D405/10 ,  C07D409/08 ,  C07D413/04 ,  C07D417/08 ,  A61P25/00 ,  A61K31/55

公开(公告)号：EP4438041A3

公开(公告)日：2025-01-01

申请号：EP24181501.8

申请日：2017-02-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： FUJIMOTO, Tatsuhiko ,  RIKIMARU, Kentaro ,  FUKUDA, Koichiro ,  SUGIMOTO, Hiromichi ,  MATSUMOTO, Takahiro ,  TOKUNAGA, Norihito ,  HIROZANE, Mariko

IPC: A61K31/435 ,  C07D213/74 ,  C07D211/24 ,  C07D211/36 ,  C07D211/56 ,  C07D401/12 ,  C07D401/14 ,  C07D401/06 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14

Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I):

wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

公开(公告)号：EP2980089A1

公开(公告)日：2016-02-03

申请号：EP14773826.4

申请日：2014-03-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： YOSHIDA, Masato ,  NAGAMIYA, Hiroyuki ,  OHBA, Yusuke ,  SETO, Masaki ,  YOGO, Takatoshi ,  SASAKI, Satoshi ,  TOKUNAGA, Norihito ,  ASO, Kazuyoshi

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/438 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/553 ,  A61P1/04 ,  A61P17/00 ,  A61P17/06 ,  A61P19/08 ,  A61P25/00 ,  A61P29/00 ,  A61P37/02 ,  A61P37/06 ,  A61P43/00 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I)

wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract translation: 本发明提供JAK抑制作用优异的化合物或其盐，作为自身免疫性疾病（类风湿性关节炎，银屑病，炎症性肠病，舍格伦氏综合征，白塞氏综合征，多发性硬化症，系统性红斑狼疮）的预防或治疗剂有用 红斑狼疮等），癌症（白血病，子宫平滑肌肉瘤，前列腺癌，多发性骨髓瘤，恶病质，骨髓纤维化等）等。 本发明涉及由式（I）表示的化合物或其盐，其中每个符号如本说明书中所定义。

公开(公告)号：EP4438041A2

公开(公告)日：2024-10-02

申请号：EP24181501.8

申请日：2017-02-01

Applicant: Takeda Pharmaceutical Company Limited

Inventor： FUJIMOTO, Tatsuhiko ,  RIKIMARU, Kentaro ,  FUKUDA, Koichiro ,  SUGIMOTO, Hiromichi ,  MATSUMOTO, Takahiro ,  TOKUNAGA, Norihito ,  HIROZANE, Mariko

IPC: A61K31/435

CPC classification number: C07D211/36 ,  C07D211/24 ,  C07D211/56 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14 ,  A61P25/00

Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I):

wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.